Treatment of social phobia with gabapentin: A placebo-controlled study

Atul C. Pande, Jonathan R T Davidson, James W. Jefferson, Carol A. Janney, David J Katzelnick, Richard H. Weisler, John H. Greist, Suzanne M. Sutherland

Research output: Contribution to journalArticle

377 Citations (Scopus)

Abstract

A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of social phobia. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3,600 mg daily in three divided doses) or placebo for 14 weeks. A significant reduction (p < 0.05) in the symptoms of social phobia was observed among patients on gabapentin compared with those on placebo as evaluated by clinician- and patient-rated scales. Results were similar for the intent-to-treat and week-2 completer populations. Adverse events were consistent with the known side effect profile of gabapentin. Dizziness (p = 0.05), dry mouth (p = 0.05), somnolence, nausea, flatulence, and decreased libido occurred at a higher frequency among patients receiving gabapentin than among those receiving placebo. No serious adverse events or deaths were reported. On the basis of these limited data, it seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia. Further studies are required to confirm this effect and to determine whether a dose-response relationship exists.

Original languageEnglish (US)
Pages (from-to)341-348
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume19
Issue number4
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Placebos
Therapeutics
Flatulence
Libido
Dizziness
Nausea
Mouth
Social Phobia
gabapentin
Odds Ratio
Safety
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., ... Sutherland, S. M. (1999). Treatment of social phobia with gabapentin: A placebo-controlled study. Journal of Clinical Psychopharmacology, 19(4), 341-348. https://doi.org/10.1097/00004714-199908000-00010

Treatment of social phobia with gabapentin : A placebo-controlled study. / Pande, Atul C.; Davidson, Jonathan R T; Jefferson, James W.; Janney, Carol A.; Katzelnick, David J; Weisler, Richard H.; Greist, John H.; Sutherland, Suzanne M.

In: Journal of Clinical Psychopharmacology, Vol. 19, No. 4, 08.1999, p. 341-348.

Research output: Contribution to journalArticle

Pande, AC, Davidson, JRT, Jefferson, JW, Janney, CA, Katzelnick, DJ, Weisler, RH, Greist, JH & Sutherland, SM 1999, 'Treatment of social phobia with gabapentin: A placebo-controlled study', Journal of Clinical Psychopharmacology, vol. 19, no. 4, pp. 341-348. https://doi.org/10.1097/00004714-199908000-00010
Pande, Atul C. ; Davidson, Jonathan R T ; Jefferson, James W. ; Janney, Carol A. ; Katzelnick, David J ; Weisler, Richard H. ; Greist, John H. ; Sutherland, Suzanne M. / Treatment of social phobia with gabapentin : A placebo-controlled study. In: Journal of Clinical Psychopharmacology. 1999 ; Vol. 19, No. 4. pp. 341-348.
@article{c0365e8558d34aa2801855ca1e832dbd,
title = "Treatment of social phobia with gabapentin: A placebo-controlled study",
abstract = "A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of social phobia. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3,600 mg daily in three divided doses) or placebo for 14 weeks. A significant reduction (p < 0.05) in the symptoms of social phobia was observed among patients on gabapentin compared with those on placebo as evaluated by clinician- and patient-rated scales. Results were similar for the intent-to-treat and week-2 completer populations. Adverse events were consistent with the known side effect profile of gabapentin. Dizziness (p = 0.05), dry mouth (p = 0.05), somnolence, nausea, flatulence, and decreased libido occurred at a higher frequency among patients receiving gabapentin than among those receiving placebo. No serious adverse events or deaths were reported. On the basis of these limited data, it seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia. Further studies are required to confirm this effect and to determine whether a dose-response relationship exists.",
author = "Pande, {Atul C.} and Davidson, {Jonathan R T} and Jefferson, {James W.} and Janney, {Carol A.} and Katzelnick, {David J} and Weisler, {Richard H.} and Greist, {John H.} and Sutherland, {Suzanne M.}",
year = "1999",
month = "8",
doi = "10.1097/00004714-199908000-00010",
language = "English (US)",
volume = "19",
pages = "341--348",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Treatment of social phobia with gabapentin

T2 - A placebo-controlled study

AU - Pande, Atul C.

AU - Davidson, Jonathan R T

AU - Jefferson, James W.

AU - Janney, Carol A.

AU - Katzelnick, David J

AU - Weisler, Richard H.

AU - Greist, John H.

AU - Sutherland, Suzanne M.

PY - 1999/8

Y1 - 1999/8

N2 - A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of social phobia. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3,600 mg daily in three divided doses) or placebo for 14 weeks. A significant reduction (p < 0.05) in the symptoms of social phobia was observed among patients on gabapentin compared with those on placebo as evaluated by clinician- and patient-rated scales. Results were similar for the intent-to-treat and week-2 completer populations. Adverse events were consistent with the known side effect profile of gabapentin. Dizziness (p = 0.05), dry mouth (p = 0.05), somnolence, nausea, flatulence, and decreased libido occurred at a higher frequency among patients receiving gabapentin than among those receiving placebo. No serious adverse events or deaths were reported. On the basis of these limited data, it seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia. Further studies are required to confirm this effect and to determine whether a dose-response relationship exists.

AB - A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of social phobia. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3,600 mg daily in three divided doses) or placebo for 14 weeks. A significant reduction (p < 0.05) in the symptoms of social phobia was observed among patients on gabapentin compared with those on placebo as evaluated by clinician- and patient-rated scales. Results were similar for the intent-to-treat and week-2 completer populations. Adverse events were consistent with the known side effect profile of gabapentin. Dizziness (p = 0.05), dry mouth (p = 0.05), somnolence, nausea, flatulence, and decreased libido occurred at a higher frequency among patients receiving gabapentin than among those receiving placebo. No serious adverse events or deaths were reported. On the basis of these limited data, it seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia. Further studies are required to confirm this effect and to determine whether a dose-response relationship exists.

UR - http://www.scopus.com/inward/record.url?scp=0032789136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032789136&partnerID=8YFLogxK

U2 - 10.1097/00004714-199908000-00010

DO - 10.1097/00004714-199908000-00010

M3 - Article

C2 - 10440462

AN - SCOPUS:0032789136

VL - 19

SP - 341

EP - 348

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -